×
Lipocine Price to Free Cash Flow Ratio 2012-2025 | LPCN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Lipocine price to free cash flow ratio from 2012 to 2025. Price to free cash flow ratio can be defined as
View More
Lipocine Price to Free Cash Flow Ratio 2012-2025 | LPCN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Lipocine price to free cash flow ratio from 2012 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.7B
Zoetis (ZTS)
$67.1B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$45.5B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$20.4B
Merck (MKKGY)
$16.9B
Shionogi (SGIOY)
$15B
United Therapeutics (UTHR)
$13.4B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.5B
IPSEN (IPSEY)
$10.8B
Stevanato Group S.p.A (STVN)
$7.9B
Corcept Therapeutics (CORT)
$7.3B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.6B
Madrigal Pharmaceuticals (MDGL)
$6.5B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.3B
Hypermarcas (HYPMY)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B